Skip to main content
. 2017 Nov 7;7:14634. doi: 10.1038/s41598-017-12660-5

Figure 3.

Figure 3

Serum miR-92b-3p expression levels and dynamics in synovial sarcoma patients in the validation cohort. (A) Serum miR-92b-3p expression levels in SS patients and control individuals in the validation cohort (p < 0.05) *p < 0.05; one-way ANOVA with Holm-Sidak’s multiple comparison test. (B) Receiver operating characteristic (ROC) curve analysis. ROC curve analysis indicated the AUC of 0.77 (95% confidence interval = 0.61–0.94) discriminating SS from age-matched benign tumour patients and healthy individuals. (CF) Tumour monitoring of serum miR-92b-3p levels during multimodal therapies. Four SS patients including an 11 year old male with lower back involvement (C), 39 year old female (groin region) (D), 61 year old female (proximal thigh) (E), and 21 year old male (knee joint) (F) could be evaluated during the treatment. Abbreviations: WBC = white blood cell; Hb = hemoglobin; OP = operative surgery; Cx = chemotherapy; Rec = recurrence; Mets = metastasis; SD = stable disease; PD = progressive disease.